Immatics (IMTX) Depreciation & Amortization (CF) (2019 - 2025)
Immatics (IMTX) posted Depreciation & Amortization (CF) of $3.7 million for Q4 2025, up 2.95% sequentially from $3.6 million in Q3 2025, and up 12.23% YoY from $3.3 million in Q4 2024.
Immatics (IMTX) Depreciation & Amortization (CF) (2019 - 2025) Analysis & Trends
Immatics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $3.7 million in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 12.23% year-over-year to $3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.0 million (up 5.8% YoY) and the FY2025 annual result came in at $14.0 million, up 5.88% from the prior year.
- Depreciation & Amortization (CF) improved to $3.7 million in Q4 2025 per IMTX's latest filing, from $3.6 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $3.7 million in Q4 2025 and troughed at -$5.8 million in Q4 2023.
- A 5-year average of $2.0 million and a median of $2.0 million in 2021 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) tumbled 427.09% in 2023, then jumped 156.32% in 2024.
- Over 5 years, Depreciation & Amortization (CF) stood at $1.5 million in 2021, then increased by 20.64% to $1.8 million in 2022, then sank by 427.09% to -$5.8 million in 2023, then surged by 156.32% to $3.3 million in 2024, then rose by 12.23% to $3.7 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3.7 million, $3.6 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.69 Mn |
| Dec 31, 2025 | 3.69 Mn |
| Sep 30, 2025 | 3.58 Mn |
| Sep 30, 2025 | 3.58 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | -5.84 Mn |
| Dec 31, 2023 | -5.84 Mn |
| Sep 30, 2023 | 1.92 Mn |
| Sep 30, 2023 | 1.92 Mn |